Nevro Corp
NYSE:NVRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nevro Corp
Depreciation & Amortization
Nevro Corp
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nevro Corp
NYSE:NVRO
|
Depreciation & Amortization
-$2.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Depreciation & Amortization
-$897m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Depreciation & Amortization
-$732m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-13%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Depreciation & Amortization
-$1.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-11%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Depreciation & Amortization
-$700k
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nevro Corp
Glance View
Nevro Corp. engages in the provision of medical devices. The company is headquartered in Redwood City, California and currently employs 945 full-time employees. The company went IPO on 2014-11-06. The firm has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform, which is in addition to the Senza family of products. The Company’s solution for chronic pain includes 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the best clinical evidence available. The advantages of its 10 kHz Therapy over traditional SCS include demonstrated superior efficacy data for both leg and back pain, paresthesia free pain relief for patients, anatomical lead placement for physicians, and ability to treat a broader group of chronic pain patients.
See Also
What is Nevro Corp's Depreciation & Amortization?
Depreciation & Amortization
-2.9m
USD
Based on the financial report for Dec 31, 2024, Nevro Corp's Depreciation & Amortization amounts to -2.9m USD.
What is Nevro Corp's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 1Y
-1 098%
Over the last year, the Depreciation & Amortization growth was -1 098%.
